Treatment patterns and survival in an exhaustive French cohort of pazopanib-eligible patients with metastatic soft tissue sarcoma (STS)

Table 5 Treatment outcomes by systemic treatment line

	1st systemic treatment line	2nd systemic treatment line	3rd systemic treatment line	4th systemic treatment line
	N = 107 (MD = 38)	N = 59	N = 34	N = 18
Time to relapse (months; median [range])	10.6 [1.1–72.2]	8.0 [1.4–27.4]	3.7 [0.5–27.7]	6.8 [1.6–21.5]
Treatment-free interval^a	N = 19	N = 58	N = 33	N = 18
(months; median [range])	10.7 [0.7–49.0]	2.8 [0.0–19.6]	1.4 [0.0–18.4]	1.0 [0.0–5.8]
Response at end of therapy	N = 102	N = 57	N = 32	N = 16
Complete response (CP)	3 (2.9%)	None	None	None
Partial response (PR)	21 (20.6%)	6 (10.5%)	None	None
Stable disease (SD)	22 (21.6%)	7 (12.3%)	5 (15.6%)	2 (12.5%)
Progressive disease	56 (54.9%)	44 (77.2%)	27 (84.4%)	14 (87.5%)
CP + PR	24 (23.5%)	6 (10.5%)	None	None
CP + PR + SD	46 (45.1%)	13 (22.8%)	5 (15.6%)	2 (12.5%)

^aTime between the end of the previous systemic treatment and the start of the current treatment line

ISSN: 1471-2407